Vaccine News and Research

Latest Vaccine News and Research

Research Roundup: Primary care doc pay and satisfaction; fixes to Medicare reimbursements; free vaccines?

A critical element of improving population health in underserved areas is the adequacy and distribution of the primary care physician supply, write the authors of this study, who interviewed 42 primary care physicians from both underserved and non-underserved areas in Los Angeles County, California.

30 Oct 2010

Progress update on Johnson & Johnson and Crucell's public offer

Pursuant to the provisions of Section 7 paragraph 1(a) of the Dutch Decree on Public Takeover Bids (Besluit Openbare Biedingen Wft) requiring a public announcement within four weeks following the announcement of an intended public offer to provide a status update, Johnson & Johnson (NYSE: JNJ) and Crucell N.V. provide the following joint update.

30 Oct 2010

Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting

Idera Pharmaceuticals, Inc. today announced a presentation describing the chemistry and immunological activity of its proprietary Toll-Like Receptor (TLR) 3 agonist compounds and the use of these compounds as vaccine adjuvants in a preclinical model.

30 Oct 2010

Advaxis enters CRADA with NCI for development of live attenuated Listeria vaccines

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, is pleased to announce it has signed a formal research agreement with the National Cancer Institute at the National Institutes of Health.

30 Oct 2010

Recent releases in Global Health

Global Fund Will Make 'Every Possible Effort' To Raise Additional Resources: Although pledges to the Global Fund to Fight AIDS, Tuberculosis and Malaria at its recent replenishment meeting did not meet "the lowest estimate of demand," the Fund "will make every possible effort to raise the additional resources that we expect countries to request in the years ahead" through new donor recruitment and "innovative financing approaches," writes Executive Director Michael Kazatchkine in a Lancet comment

30 Oct 2010

Drug and device makers face new taxes, fees

A Fox Business report shows the health overhaul is cutting deeper into drug and device makers' profits than many expected. Research & development programs are already being drastically scaled back.

30 Oct 2010

PharmAthene prices registered public offering

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has priced a registered public offering of 4,300,000 shares of its common stock at a price to the public of $3.50 per share.

29 Oct 2010

Merck reports $342 million net income for 2010 third quarter

Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.

29 Oct 2010

Henry Schein third quarter net sales increases 14.1% to $1.9 billion

Henry Schein, Inc. the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended September 25, 2010.

29 Oct 2010

ImmuneRegen's Homspera enhances survival of animals vaccinated with experimental melanoma vaccine

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR BioSciences Holdings, Inc., today announced that treatment with its lead compound, Homspera®, improved the survival of animals vaccinated with an experimental melanoma vaccine.

29 Oct 2010

China CDC signs collaborative agreement with Hutchinson Cancer Research Center

The Chinese Center for Disease Control and Prevention (China CDC) and Fred Hutchinson Cancer Research Center today formalized an ongoing relationship by signing a collaboration agreement. It marks the first such agreement between the China CDC and a U.S. cancer research center.

29 Oct 2010

Scientists develop new method to analyze early detection of virus

The virus, called enterovirus 71, is closely related to poliovirus, and was first detected in California in the 1960s. Since then the virus has spread across Asia, affecting mostly children and some adults. Serious cases of the disease can include neurological disorders such as meningitis, paralysis and encephalitis.

29 Oct 2010

Research on sheep population could help explain variation in vaccine protection

Strong immunity may play a key role in determining long life, but may do so at the expense of reduced fertility, a Princeton University study has concluded.

29 Oct 2010

Scientists identify potential new treatment for Nipah and Hendra viruses

Scientists at Weill Cornell Medical College have identified a potential new treatment for the Nipah and Hendra viruses, two lethal and emerging viruses for which there is currently no treatment or vaccine available. The approach could also lead to new therapies for measles, mumps and the flu. The new research appears in today's edition of the prestigious journal Public Library of Science (PLoS) Pathogens.

29 Oct 2010

Researchers depict new statistical algorithm to identify genetic variations for common diseases

A group of researchers at The Scripps Research Institute and the Scripps Translational Science Institute has published a paper that reviews new strategies for identifying collections of rare genetic variations that reveal whether people are predisposed to developing common conditions like diabetes and cancer.

29 Oct 2010

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

Antigenics third quarter net loss decreases from $10.8 million to $5.9 million

Antigenics Inc. reported today its results for the quarter ended September 30, 2010. The company incurred a net loss attributable to common stockholders of $5.9 million, or $0.06 per share, basic and diluted, for the third quarter of 2010, compared with a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, in the third quarter of 2009.

28 Oct 2010

New nationwide initiative to conduct research on human immune system

A new nationwide research initiative has been launched to define changes in the human immune system's response to infection and vaccination using human rather than animal models, which could lead to better vaccines and other treatments. Baylor Research Institute (BRI), along with five other U.S.-based Human Immune Phenotyping Centers, will receive a total of $100 million over five years to conduct the research.

28 Oct 2010

NMA/NBNA releases new consensus report on RSV

Today, the National Medical Association (NMA) and the National Black Nurses Association (NBNA) released a consensus report on RSV. Concerned that recent clinical guidelines published by the American Academy of Pediatrics Committee of Infectious Disease (AAP/COID) may leave some infants unprotected from RSV, the NMA/NBNA RSV Consensus Panel recommended that additional research be conducted to ensure that physicians provide the maximum protection to infants and children at risk of RSV.

28 Oct 2010

Max Planck Innovation licenses new software for metabolite analysis

Max Planck Innovation licenses analysis-technology for metabolites . Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical research.

28 Oct 2010